Contents
Overview
ZENAPAX 25MG INJ is a Schedule H drug.ZENAPAX 25MG INJ is composed of: DACLIZUMAB (25.0 MG)
Daclizumab is a monoclonal antibody that affects the actions of the body’s immune system. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. Daclizumab is used to treat relapsing forms of multiple
Usage
DACLIZUMAB is generally used to treat: Multiple SclerosisFrequently Asked Questions
Q: Is it safe for children?A: Ask your doctor
Q: Can it be taken during pregnancy?
A: Considered as Generally Safe – not enough studies to prove risk
Precautions
Do not receive a "live" vaccine while using daclizumab and for at least 4 months after your last dose. Caution should be exercised in patients with any allergy, during pregnancy and breastfeeding. It may cause dizziness or blurred vision, do not drive a car or operate machinery while taking this medication. It may affect blood sugar level; monitor sugar level regularly while taking this medication.
Common Side-Effects
DACLIZUMAB : Dark Colored (brown) Urine, Fatigue (tiredness), Weakness (generalized), Loss Of Appetite, Abdomen Pain, Vomit, Eyes Yellow EyesSerious Side-Effects
DACLIZUMAB : Cloudy Urine With Strong Odor, Body Pain, Cough, Hoarse Voice, Head Headache, Nasal Congestion, Runny Nose, Throat SorenessRare Side-Effects
DACLIZUMAB : Frightening Thoughts, Bloody Or Red Colored StoolsDisease Interactions
DACLIZUMAB can interfere with: Depression, Bacterial Infection, Fungal Infection, Acute Liver Failure, Tuberculosis, Psoriasis, EczemaTechnical Classification
DACLIZUMAB is categorized as: SELECTIVE IMMUNOSUPPRESSANTS / IMMUNOSUPPRESSIVE AGENTS / IMMUNOLOGIC AGENTSAvailable Alternatives
What are the commonly available Substitutes?
DACLIZUMAB | DACLIZUMAB | |
ZENAPAX 25MG INJ | INR 23920 for 5 ML INJECTION | DACLIZUMAB 25.0 MG |